LGP holds all licences and permits required in Australia to cultivate, produce and sell medicinal cannabis products, and all licences to import and export medicinal cannabis products offshore. LGP’s Manufacturing Partner holds all relevant licences to import and export medicinal cannabis products as well as all licences and permits to manufacture and distribute finished medicinal cannabis products for LGP.
LGP currently sells and distributes its medicinal cannabis products in Australia through Oxford Compounding Pty Ltd for patients in Western Australia and Health House International Pty Ltd for patients in other states and territories. As of October 2019, LGP products have been used by more than 1,400 patients in Australia, with over 4,500 bottles of medicinal cannabis oil sold.
LGP aims to take advantage of opportunities relating to the emerging medicinal cannabis industry in Australia and in certain international jurisdictions.
It is anticipated that LGP will list on the ASX during February 2020.